Physician profile
Emile C Salloum
NPI 1144209024
$26,439.98
in general payments reported to CMS, 2019-2025
72 companies · $5,152 in 2025
The $5,152 reported for 2025 was more than what 82% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,503 · 2020: $2,178 · 2021: $3,371 · 2022: $3,786 · 2023: $3,728 · 2024: $4,721 · 2025: $5,152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,640.06 |
| Education | $961.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,415.17 | 2019-2025 | Opdivo, Opdualag, Breyanzi |
| Astrazeneca Pharmaceuticals Lp | $2,101.16 | 2019-2025 | Enhertu, Calquence, Imfinzi |
| Merck Sharp & Dohme LLC | $1,931.44 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $1,664.07 | 2019-2025 | |
| Janssen Biotech, INC. | $1,456.55 | 2019-2025 | Darzalex, Erleada, Tecvayli |
| Pfizer INC. | $1,319.65 | 2019-2025 | |
| Celgene Corporation | $853.51 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Incyte Corporation | $826.90 | 2019-2025 | Monjuvi, Jakafi |
| Eisai INC. | $807.50 | 2019-2025 | |
| Genzyme Corporation | $768.27 | 2019-2025 | |
| Seagen INC. | $728.98 | 2019-2025 | Adcetris, Tukysa, Padcev |
| Genentech USA, INC. | $658.53 | 2019-2025 | Tecentriq, Polivy, Lunsumio |
| Astellas Pharma US INC | $634.08 | 2019-2025 | Vyloy, Xtandi, Padcev |
| Karyopharm Therapeutics INC. | $630.16 | 2020-2025 | Xpovio |
| Daiichi Sankyo INC. | $624.44 | 2020-2025 | Enhertu, Datroway |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $607.38 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Takeda Pharmaceuticals U.S.A., INC. | $551.12 | 2019-2025 | Iclusig, Ninlaro, Fruzaqla |
| Gilead Sciences, INC. | $533.31 | 2019-2025 | Trodelvy |
| Abbvie INC. | $487.45 | 2019-2025 | Venclexta |
| Bayer Healthcare Pharmaceuticals INC. | $450.55 | 2019-2025 | |
| Glaxosmithkline, LLC. | $418.51 | 2020-2025 | Ojjaara, Zejula, Shingrix |
| Taiho Oncology, INC. | $409.89 | 2019-2025 | |
| Exelixis INC. | $362.14 | 2019-2025 | Cabometyx |
| Sanofi-Aventis U.S. LLC | $314.60 | 2019-2025 | |
| Puma Biotechnology, INC. | $276.50 | 2019-2025 | Nerlynx |
| Ipsen Biopharmaceuticals, INC | $271.37 | 2021-2025 | Onivyde, Somatuline Depot |
| Pharmacyclics LLC, An Abbvie Company | $268.49 | 2019-2023 | Imbruvica |
| Array Biopharma INC | $267.82 | 2022-2025 | Braftovi, Mektovi, Lorbrena |
| Regeneron Healthcare Solutions, INC. | $258.07 | 2021-2024 | Libtayo |
| Kite Pharma, INC. | $249.30 | 2019-2025 | Yescarta |
| Organon LLC | $236.69 | 2021-2025 | Ontruzant |
| Pharmaessentia USA Corporation | $211.49 | 2022-2025 | Besremi |
| Adc Therapeutics America, INC. | $209.69 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.52 | 2019-2023 | Gilotrif |
| Emd Serono, INC. | $186.41 | 2019-2025 | Bavencio |
| Stryker Corporation | $169.87 | 2024 | Spy-Phi System |
| Beigene USA, INC. | $137.85 | 2020-2024 | Brukinsa |
| Mirati Therapeutics, INC. | $132.25 | 2023-2024 | Krazati |
| Morphosys, US INC. | $131.26 | 2021-2024 | Monjuvi |
| Genmab U.S., INC. | $123.55 | 2025 | Epkinly |
| Rigel Pharmaceuticals, INC. | $120.80 | 2021-2025 | Rezlidhia, Tavalisse, Gavreto |
| Sobi, INC | $120.33 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $115.81 | 2022-2025 | |
| Dova Pharmaceuticals | $102.48 | 2019-2021 | |
| Aveo Pharmaceuticals, INC. | $97.63 | 2022-2023 | Fotivda |
| Stemline Therapeutics INC. | $93.93 | 2023-2025 | Orserdu |
| Coherus Oncology, INC. | $84.89 | 2020-2024 | |
| Clovis Oncology, INC. | $80.70 | 2019-2021 | |
| Tesaro, INC. | $72.76 | 2019 | |
| Mylan Institutional INC. | $71.94 | 2021-2023 | Fulphila, Ogivri |
| Teva Pharmaceuticals USA, INC. | $63.51 | 2019-2021 | |
| Tolmar, INC. | $48.27 | 2023-2025 | Rubraca, Eligard |
| Beone Medicines USA, INC. | $45.85 | 2025 | Brukinsa |
| Geron Corporation | $42.80 | 2025 | Rytelo |
| Myovant Sciences INC. | $37.84 | 2021 | |
| Blueprint Medicines Corporation | $33.36 | 2021-2022 | |
| Pharmaand Gmbh | $33.19 | 2025 | Rubraca |
| Janssen Pharmaceuticals, INC | $30.54 | 2019-2024 | Rybrevant |
| Sandoz INC. | $29.03 | 2020-2021 | |
| Epizyme, INC. | $28.40 | 2021-2022 | |
| Acceleron Pharma, INC. | $23.29 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $21.79 | 2020 | |
| Immunogen, INC. | $19.63 | 2023 | Elahere |
| Tg Therapeutics, INC. | $18.91 | 2021 | |
| Sun Pharmaceutical Industries INC. | $18.56 | 2024 | |
| Immunomedics, INC. | $18.42 | 2020 | |
| Shield Therapeutics INC | $15.47 | 2024 | |
| Springworks Therapeutics, INC. | $14.81 | 2024 | Ogsiveo |
| Acrotech Biopharma INC. | $14.53 | 2021 | |
| Secura Bio, INC. | $13.75 | 2022 | |
| Pharmacosmos Therapeutics INC. | $13.03 | 2021 | |
| Verastem, INC. | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emile Salloum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.